Active Specific Immunotherapy in Renal Cell Carcinoma: Optimization

  • C. S. McCune
Conference paper

Abstract

The requirements for effective cancer vaccines have gradually been worked out in experimental models over the past 15 years [1–3]. Many clinical trials in this field were initiated before this information was available or did not adhere to the methodologic requirements that had been found in the animal studies. As a consequence, there are several negative clinical investigations of active specific immunotherapy in which failure was a virtual certainty [4–6] when looked at in retrospect with regard to the requirements that have been identified in animal models. Some of the key requirements are as follows.

Keywords

Bacillus Sarcoma Cyclophosphamide Allo Mycobacterium 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bartiett GL, Zbar B (1972) Tumor-specific vaccine containing mycobacterium bovis and tumor cells: safety and efficacy. J Natl Cancer Inst 48: 1709–1726Google Scholar
  2. 2.
    Scott MT (1975) Potentiation of the tumor–specific immune response by Corynebacterium parvum. J Natl Can Inst 55: 65–72Google Scholar
  3. 3.
    Hanna MG, Peters LC (1981) Morphological and functional aspects of active specific immunotherapy of established pulmonary metastases in guinea pigs. Cancer Res 41: 4001–4009PubMedGoogle Scholar
  4. 4.
    Hudson CN, McHardy JE, Curling OM etal. (1976) Active specific immunotherapy for ovarian cancer. Lancet 7991: 877–879CrossRefGoogle Scholar
  5. 5.
    Newlands ES, Oon CJ, Roberts JT etal. (1976) Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma. Br J Cancer 34: 174–179PubMedCrossRefGoogle Scholar
  6. 6.
    Gray BN, Walker C, Andrewartha L etal. (1988) Melbourne trial of adjuvant immunotherapy in operable large bowel cancer. Aust NZ J Surg 58: 43–46CrossRefGoogle Scholar
  7. 7.
    Tykka H, Oravisto KJ, Lehtonen T etal. (1978) Active specific immunotherapy of advanced renal-cell carcinoma. Eur Urol 4: 250–258PubMedGoogle Scholar
  8. 8.
    McCune CS, Schapira DV, Henshaw EC (1981) Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 47: 1984–1987PubMedCrossRefGoogle Scholar
  9. 9.
    Sahasrabudhe DM, deKernion JB, Pontes JE etal. (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Resp Mod 5: 581–594Google Scholar
  10. 10.
    Neidhart JA, Gagen M, Young D, Wise H (1983) A randomized study of polymerized tumor antigen admixed with adjuvant for therapy of renal cancer. Proc Am Soc Clin Oncol 2: 49Google Scholar
  11. 11.
    Adler A, Gillon G, Lurie H etal. (1987) Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormone-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Resp Mod 6: 610–624Google Scholar
  12. 12.
    Scharfe T, Muller S, Riedmiller H etal. (1989) Immunotherapy of metastasizing renal cell carcinoma. Urol Int 44: 1–4PubMedCrossRefGoogle Scholar
  13. 13.
    Hoover HC, Surdyke M, Dangel RB etal. (1984) Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guerin vaccine. Cancer Res 44: 1671–1676Google Scholar
  14. 14.
    Hoover HC, Surdyke MG, Dangel RB etal. (1985) Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55: 1236–1243PubMedCrossRefGoogle Scholar
  15. 15.
    Berd D, Maguire HC, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46: 2572–2577PubMedGoogle Scholar
  16. 16.
    Mitchell MS, Kan-Mitchell J, Kempf RA etal. (1988) Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48: 5883–5893PubMedGoogle Scholar
  17. 17.
    McCune CS, Marquis DM (1990) Interleukin-1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res 50: 1212–1215PubMedGoogle Scholar
  18. 18.
    Law LS (1980) Changes in tumor-specific antigen expression during passage in vitro and in vivo of newly derived methylcholanthrene-induced sarcomas of Balb/C mice. Int J Cancer 25: 251–259PubMedCrossRefGoogle Scholar
  19. 19.
    Economou GC, Takeichi N, Boone CW (1977) Common tumor rejection antigens in methylcholanthrene-induced squamous cell carcinomas of mice detected by tumor protection and a radioisotopic footpad assay. Cancer Res 37: 37–41PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • C. S. McCune
    • 1
  1. 1.Medical Oncology DivisionUniversity of Rochester Medical CenterRochesterUSA

Personalised recommendations